Pharmaron (03759) reported that shareholders endorsed all 15 resolutions at the 2025 Annual General Meeting held on 12 June 2026 in Beijing.
Voting profile • Valid voting share capital: 1.83 billion shares (treasury shares excluded) • Shares present or represented: 891.12 million, equal to 48.69 % of voting shares • All nine ordinary and six cumulative-vote items received well above the simple-majority threshold; four special resolutions each surpassed the two-thirds requirement. • The general issuance mandate (Special Resolution 13) passed with 90.97 % support, authorising future share issuance up to 1.83 billion shares.
Profit distribution • Shareholders approved a cash dividend of RMB0.20 per share, totalling approximately RMB366.00 million (tax inclusive). • Record date: 15 July 2026; payment via CMB Wing Lung Bank is slated for on or about 7 August 2026. • H-share dividends will be paid in Hong Kong dollars, converted at the PBoC’s five-day average rate of RMB0.869840 per HK$1.
Board elections • Executive Directors (cumulative voting): – Dr. Lou Boliang: 85.49 % of votes – Mr. Lou Xiaoqiang: 84.65 % – Ms. Zheng Bei: 88.68 % • Non-executive Director: Ms. Wan Xuan (99.49 % support). • Independent Non-executive Directors: – Ms. Li Lihua: 88.67 % – Prof. Tsang King Fung: 89.45 % – Ms. Shen Rong: 89.45 % The fourth Board session will serve a three-year term commencing immediately. Executive and employee directors will receive role-based remuneration comprising salary and performance bonus; independent directors will receive an annual fee of RMB0.35 million.
Other key approvals • 2026 hedging quota, external guarantees cap and auditor appointments for domestic, internal control and international audits all carried with at least 99 % support. • Shareholders endorsed increasing registered capital and corresponding amendments to the Articles of Association, completing the governance updates outlined in the May 2026 circular.
With the AGM decisions in force, Pharmaron enters its new board term funded by a RMB366 million payout to shareholders and equipped with refreshed mandates for capital management and risk‐mitigation measures.